Results 241 to 250 of about 9,316,170 (262)

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Febrile status epilepticus and epileptogenesis: The FEBSTAT study

Epilepsia Open, EarlyView.
Abstract The multicenter FEBSTAT study (Consequences of Prolonged Febrile Seizures in Childhood: https://grantome.com/grant/NIH/R37‐NS043209‐12; PI S. Shinnar) examined the outcome of febrile status epilepticus (FSE) in over 200 prospectively enrolled infants, with many followed for 10 years after FSE.
Darrell V. Lewis, Douglas R. Nordli Jr., Douglas R. Nordli III, Shlomo Shinnar, Stephen Chan, Jacqueline A. Bello, L. Matthew Frank, James Voyvodic, William Gallentine, Syndi Seinfeld, Yoshimi Sogawa, Erica Weiss, David Masur, Yuan Xu, Solomon L. Moshé   +14 more
wiley   +1 more source

Prenatal betamethasone–postnatal N‐methyl‐D‐aspartic acid model of spasms: Update on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Infantile epilepsy spasms syndrome (IESS), formerly known as infantile spasms or West Syndrome, is a severe epilepsy syndrome affecting about 3 in 10,000 newborns in the United States. Characterized by clusters of epileptic spasms, interictal hypsarrhythmia, and developmental delays, IESS has diverse causes, including structural‐metabolic ...
Kayla Vieira, Antonia Schonwald, Chian‐Ru Chern, Kamya Shah, Jana Velíšková, Libor Velíšek   +5 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?

Multiple Sclerosis Journal, 2021
Olga Ciccarelli, Yael Hacohen, Omar Abdel-Mannan   +2 more
exaly  

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

New England Journal of Medicine, 2017
Fred D. Lublin, Bernhard Hemmer, Amit Bar-or   +2 more
exaly  

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

Brain, 1999
George C. Ebers, J Baskerville, G P Rice
exaly  

The pathology of primary progressive multiple sclerosis

Multiple Sclerosis Journal, 2002
Hans Lassmann, C Lucchinetti
exaly  

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Lancet, The, 2016
Fred D. Lublin, Catherine Lubetzki, Bruce A C Cree   +2 more
exaly  

Natural history of primary progressive multiple sclerosis

Multiple Sclerosis Journal, 2004
George C. Ebers
exaly  

Primary progressive multiple sclerosis: a 5‐year clinical and MR study

Brain, 2003
Alan J. Thompson, V L Stevenson, G T Ingle   +2 more
exaly